Clinical Observation Of Zhuanggan Zhuyu Decoction Combined With Entecavir In The Treatment Of Decompensated Period Of Hepatic Cirrhosis With Deficiency And Stasis Type B

Objective : To observe the clinical effect of Zhuanggan Zhuyu Decoction combined with Entecavir in the treatment of decompensated liver cirrhosis with positive deficiency and stasis type B,and to evaluate its safety.Methods : 70 patients who met the inclusion criteria were selected and randomly divided into a control group and a treatment group,each with 35 patients according to the random number table method.The control group was given Entecavir dispersible tablets on the basis of conventional western medicine comprehensive treatment;the treatment group was combined with Zhuanggan Zhuyu decoction on the basis of the control group,and both groups were treated for 12 weeks.Observe the changes of TCM symptom score,liver function(ALT,AST,ALB,TBIL),blood coagulation function(PT),blood routine(WBC,RBC,HGB,PLT)of the two groups of patients before treatment,6 weeks of treatment and 12 weeks of treatment,And the changes in liver and spleen ultrasound and ascites classification before and after 12 weeks of treatment,to evaluate the clinical efficacy and safety of Zhuanggan Zhuyu Jian in the treatment of decompensated liver cirrhosis with Zhengxuyu type.Results:(1)Overall efficacy: After the end of the total treatment period,the total effective rate of the treatment group was 85.29%,and the total effective rate of the control group was 68.75%.The therapeutic effect of the treatmentgroup was better than that of the control group,and the difference was statistically significant(P <0.05).(2)TCM syndrome scores: After treatment,the symptom scores of the two groups of patients both decreased compared with before(P <0.05).Compared with the control group,the decrease of the treatment group was better than that of the control group(P <0.05).Statistical significance.(3)Liver function: After treatment,the liver function(ALT,AST,ALB,TBIL)of the two groups were significantly improved compared with before(P <0.05).Compared with the control group,the treatment group was superior in improving liver function In the control group,the differences were statistically significant(P <0.05).(4)Coagulation function(PT): After treatment,the PT of the two groups was shorter than before(P <0.05),and the PT shortening degree of the treatment group was better than that of the control group(P <0.05).Learn meaning.(5)Blood routine: After treatment,the WBC,HGB and PLT of the two groups increased compared with the previous ones,the difference was statistically significant(P <0.05);the RBC of the treatment group increased compared with the previous,the difference was statistically significant(P <0.05);There was no statistically significant difference in RBC between the control group at 6 weeks of treatment and before treatment(P> 0.05),and at 12 weeks of treatment,the difference was statistically significant compared to 6 weeks of treatment(P <0.05).Compared with the control group,the treatment group was superior to the control group in increasing WBC,RBC,HGB,and PLT,and the difference was statistically significant(P <0.05).(6)Liver and spleen ultrasound: after treatment,the inner diameter of the main trunk of the portal vein,the thickness of the spleen,and the length of the spleen of the two groups were retracted compared with that before treatment,and the blood flow velocity of the portal vein increased faster than before treatment(P <0.05).The treatmentgroup was superior to the control group in reducing the inner diameter of the main portal vein,the thickness of the spleen,and the length of the spleen,and accelerating the blood flow of the portal vein.The difference was statistically significant(P <0.05).(7)Ascites grading: The ascites grading in both groups was improved compared with before treatment(P <0.05),and the improvement in the treatment group was better than that in the control group(P <0.05).(8)Safety observation: No obvious adverse reactions occurred during the observation of the two groups of patients.Conclusion :(1)Zhuanggan Zhuyu Decoction combined with Entecavir in the decompensated period of liver cirrhosis with positive deficiency and stasis type B can improve liver function,improve blood coagulation function,and effectively relieve liver damage.(2)Zhuanggan Zhuyu Jian combined with Entecavir can improve portal hypertension and hypersplenism,and it has a better effect on the resolution of ascites.(3)Zhuanggan Zhuyu Jian combined with Entecavir can improve the clinical symptoms of patients,has better clinical efficacy,and has better safety.